- Profit after tax (consolidated)
- Rs 248.8 mn
- EPS
- Rs 1.09 +22.5%
- EPS a year earlier
- Rs 0.89
PSX Pharmaceuticals
CPHL Citi Pharma Ltd.
Latest results: FY2026 · Jun 2026
FY2026 revenue Rs 14.1 bn (+7.0%), profit Rs 790.3 mn (-11.4%).
Last close · 13 Nov 2026
Rs 63.42 ▼ 0.13 (-0.20%)
▼ 22.8% 1 year
- Market cap
- Rs 14.5 bn
- P/E
- 18.3×
- FY2026
- Sector 12.6× · higher
- P/B
- 1.34×
- FY2026
- Sector 3.11× · lower
- Dividend yield
- 0.0%
- FY2026
- ROE
- 7.3%
- FY2026
- Sector 21.7% · lower
- EPS
- Rs 3.46
- FY2026
- Book value / share
- Rs 47.42
- FY2026
Fundamentals
CPHL at a glance
Revenue · FY2026
Rs 14.1 bn
▲ 7.0% year on year
Profit attributable to shareholders · FY2026
Rs 790.3 mn
▼ 11.4% year on year
EPS – basic (Rs) · FY2026
Rs 3.46
▼ 11.4% year on year
Dividend per share (Rs) · FY2026
Rs 0.00
▼ 100.0% year on year
Net margin · FY2026
5.6%
-1.2 pts year on year
Debt to equity · FY2026
28.6%
+1.5 pts year on year
Price performance
CPHL returns
Close Rs 63.42
13 Nov 2026
| Period | Return | Rs | vs KSE-100 |
|---|---|---|---|
| MTD Month to date | +4.4% −2.5 pts vs KSE | +2.68 | −2.5 pts KSE +6.9% |
| 3M 3 months | −13.0% −11.7 pts vs KSE | −9.44 | −11.7 pts KSE −1.2% |
| 6M 6 months | −19.4% −25.6 pts vs KSE | −15.22 | −25.6 pts KSE +6.2% |
| YTD Year to date | −25.0% −27.2 pts vs KSE | −21.18 | −27.2 pts KSE +2.2% |
| FYTD Fiscal year to date | −18.6% −17.2 pts vs KSE | −14.45 | −17.2 pts KSE −1.4% |
| 1Y 1 year | −22.8% −33.5 pts vs KSE | −18.73 | −33.5 pts KSE +10.7% |
| Long term | |||
| 3Y 3 years | +152.0% +36.1% a year −62.7 pts vs KSE | +38.25 | −62.7 pts KSE +214.7% |
| 5Y 5 years | +75.5% +11.9% a year −213.3 pts vs KSE | +27.28 | −213.3 pts KSE +288.8% |
Price return from the last close before each period; the fiscal year ends 30 June. Dividends are not included.
Citi Pharma Ltd. in brief
Citi Pharma Ltd. (CPHL) reported revenue of Rs 14.1 bn for FY2026 (Jul 2025 – Jun 2026), up 7.0% from FY2025.
Profit attributable to shareholders was Rs 790.3 mn (EPS Rs 3.46), down 11.4%, a net margin of 5.6%.
No cash dividend was declared for FY2026.
Net debt stood at Rs 2.8 bn.
Return on equity was 7.3%.
Over the last five years revenue grew at a compound 19.4% a year.
At Rs 63.42 (close on 13 Nov 2026) the shares trade at 18.3× earnings (FY2026) and 1.34× book value.
Scorecard vs Pharmaceuticals
14 companies- Growth
- Weak
- 4.3%
- Profitability
- Average
- 5.6%
- Financial health
- Below average
- 28.6%
- Valuation
- Weak
- 18.3×
- Dividends
- Below average
- 0.0%
Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.
Corporate
CPHL announcements & payouts
- Profit after tax (unconsolidated)
- Rs 233.2 mn
- EPS
- Rs 1.02 +14.6%
- EPS a year earlier
- Rs 0.89
- Profit after tax (consolidated)
- Rs 790.3 mn
- EPS
- Rs 3.46 -11.3%
- EPS a year earlier
- Rs 3.90
- Profit after tax (unconsolidated)
- Rs 782.6 mn
- EPS
- Rs 3.43 -12.1%
- EPS a year earlier
- Rs 3.90
Book closure 22 Oct – 28 Oct 2026
Financial highlights
CPHL financial results
| Rs bn | FY2026 Jul 2025 – Jun 2026 | FY2025 Jul 2024 – Jun 2025 | FY2024 Jul 2023 – Jun 2024 | FY2023 Jul 2022 – Jun 2023 | FY2022 Jul 2021 – Jun 2022 | FY2021 Jul 2020 – Jun 2021 | FY2020 Jul 2019 – Jun 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.1 | 13.2 | 12.4 | 12.4 | 9.8 | 5.8 | 3.5 |
| Gross profit | 2.5 | 2.0 | 1.6 | 1.5 | 1.4 | 0.8 | 0.4 |
| Operating profit | 1.9 | 1.6 | 1.2 | 1.2 | 1.0 | 0.6 | 0.3 |
| Profit after tax | 0.8 | 0.9 | 0.8 | 0.7 | 0.7 | 0.4 | 0.1 |
| Profit attributable to shareholders | 0.8 | 0.9 | 0.8 | 0.7 | 0.7 | 0.4 | 0.1 |
| EPS – basic (Rs) Rs | 3.46 | 3.90 | 3.65 | 2.88 | 2.88 | 4.22 | 28.97 |
| Dividend per share (Rs) Rs | 0.00 | 3.50 | 3.25 | 2.50 | 0.00 | 0.00 | 0.00 |
| Total assets | 18.3 | 18.4 | 11.4 | 10.0 | 8.1 | 6.5 | 2.5 |
| Total equity | 10.8 | 10.9 | 5.6 | 5.4 | 4.7 | 4.4 | 1.0 |
| Total debt | 3.1 | 2.9 | 1.5 | 1.8 | 0.9 | 0.7 | 0.5 |
| Net cash from operating activities | 0.2 | (0.3) | 1.3 | (0.3) | (0.3) | 0.7 | 0.1 |
| Capital expenditure | (0.7) | (0.2) | (0.6) | (1.0) | (0.6) | (0.3) | (0.1) |
| Free cash flow (operating cash flow − capex) | (0.5) | (0.5) | 0.8 | (1.3) | (0.9) | 0.5 | (0.0) |
| Rs bn | TTM to Jun 2026 | Q4 FY2026 Apr – Jun 2026 | Q3 FY2026 Jan – Mar 2026 | Q2 FY2026 Oct – Dec 2025 | Q1 FY2026 Jul – Sep 2025 | Q4 FY2025 Apr – Jun 2025 | Q3 FY2025 Jan – Mar 2025 | Q2 FY2025 Oct – Dec 2024 | Q1 FY2025 Jul – Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.1 | 3.3 | 3.1 | 4.3 | 3.4 | 3.1 | 3.3 | 3.5 | 3.2 |
| Gross profit | 2.5 | 0.5 | 0.5 | 1.0 | 0.5 | 0.6 | 0.5 | 0.5 | 0.4 |
| Operating profit | 1.9 | 0.3 | 0.4 | 0.8 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 |
| Profit after tax | 0.8 | (0.1) | 0.3 | 0.4 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 |
| Profit attributable to shareholders | 0.8 | (0.1) | 0.3 | 0.4 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 |
| EPS – basic (Rs) Rs | 3.46 | (0.41) | 1.21 | 1.77 | 0.89 | 0.93 | 0.96 | 1.12 | 0.88 |
| Dividend per share (Rs) Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.50 | 0.00 | 0.00 | 0.00 |
| Total assets | 18.3 | 18.3 | 18.9 | 20.9 | 17.9 | 18.4 | 13.6 | 12.6 | 12.2 |
| Total equity | 10.8 | 10.8 | 11.0 | 10.7 | 11.1 | 10.9 | 5.6 | 5.3 | 5.8 |
| Total debt | 3.1 | 3.1 | 3.6 | 5.7 | 2.8 | 2.9 | 2.9 | 1.8 | 1.5 |
| Net cash from operating activities | 0.2 | 1.1 | (0.7) | 0.2 | (0.5) | 0.3 | (0.9) | 0.4 | (0.1) |
| Capital expenditure | (0.7) | (0.6) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.1) | (0.0) |
| Free cash flow (operating cash flow − capex) | (0.6) | 0.5 | (0.7) | 0.1 | (0.5) | 0.2 | (1.0) | 0.3 | (0.1) |
Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 17 Oct 2026.
CPHL charts
Valuation
CPHL valuation at today's price
- Price to earnings (P/E)
- 18.3×
- EPS Rs 3.46 (FY2026)
- Price to book (P/B)
- 1.34×
- Book value Rs 47.42 (FY2026)
- Dividend yield
- 0.0%
- DPS Rs 0.00 (FY2026)
- Earnings yield
- 5.5%
- EPS ÷ price
At the closing price of Rs 63.42 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.
Sector peers
CPHL vs Pharmaceuticals companies
| Company | Market cap | P/E | P/B | Yield | ROE | 3-yr growth |
|---|---|---|---|---|---|---|
| CPHL | Rs 14.5 bn | 18.3× | 1.34× | 0.0% | 7.3% | 4.3% |
| GLAXO | Rs 107.1 bn | 10.3× | 3.11× | 5.1% | 32.4% | 16.3% |
| ABOT | Rs 97.9 bn | 11.4× | 3.05× | 4.0% | 28.8% | 15.2% |
| HALEON | Rs 81.6 bn | 12.4× | 5.02× | 4.3% | 47.6% | 16.2% |
| HINOON | Rs 50.8 bn | 12.8× | 3.95× | 5.2% | 32.3% | 20.5% |
| AGP | Rs 43.8 bn | 11.7× | 2.92× | 5.1% | 25.9% | 26.0% |
| HPL | Rs 38.5 bn | 10.3× | 4.50× | 6.0% | 38.6% | 18.6% |
| FEROZ | Rs 15.8 bn | 16.1× | 1.19× | 1.5% | 7.6% | 27.9% |
| MACTER | Rs 12.0 bn | 17.7× | 2.87× | 0.0% | 17.4% | 20.7% |
Analyses & signals 0
Win rate — · 0 closed signals · average return —
No analyses published for CPHL yet.
CPHL: frequently asked questions
What is CPHL's EPS?
Citi Pharma Ltd. reported basic earnings per share of Rs 3.46 for FY2026 (Jul 2025 – Jun 2026).
What is CPHL's P/E ratio?
At the closing price of Rs 63.42 on 13 Nov 2026, CPHL trades at a P/E of 18.3× based on EPS of Rs 3.46 (FY2026).
Does CPHL pay dividends?
Citi Pharma Ltd. did not declare a cash dividend for FY2026.
What was CPHL's revenue and profit in FY2026?
Citi Pharma Ltd. reported revenue of Rs 14.1 bn and profit attributable to shareholders of Rs 790.3 mn for FY2026 (Jul 2025 – Jun 2026).
What is CPHL's book value per share?
Citi Pharma Ltd.'s book value per share was Rs 47.42 at the end of FY2026. The shares trade at 1.34× book value.
How has CPHL's share price performed?
CPHL's share price is down 25.0% year to date (KSE-100: +2.2%), down 22.8% over one year (KSE-100: +10.7%) and up 75.5% over five years (KSE-100: +288.8%), as of 13 Nov 2026. These are price returns; dividends are not included.
Information only, not investment advice.